Inhibitors of AKT, MEK, PKA, PKC and CAMKII were ineffective.11 On the basis of these considerations, it would be informative to address whether urothelial carcinomas with an active FGF-2/KDM2B-EZH2/miR-101/EZH2 axis, are sensitive to catalytic inhibitors of EZH2, in combination with inhibitors of the induction of KDM2B by FGF-2 or VEGF. This evidence concerns the gene EZH2 and urothelial carcinoma.